Coronary disease & ACSResearch article
Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction
- Phase II trial
- single-group, before–after
Authors' conclusion
This study demonstrates that the CS Reducer is associated with significant improvement in angina, quality of life, and coronary microvascular function in patients with CMD
Study context
- Population
- Patients with ANOCA, invasively diagnosed coronary microvascular dysfunction (CMD) and CCS class 3–4 angina despite medical therapy67% women
- Participants
- 30 patients
- Comparison
- Coronary sinus (CS) Reducer implantation, before vs 120 days after
- CS Reducern = 30
- Outcome
- Change in microvascular function
- Follow-up
- 120 days
Main finding
As reported in the abstract
Coronary flow reserve (CFR) in low baseline CFR (endothelium-independent CMD), n = 19: median 2.1 (1.95-2.30) to 2.7 (2.45-2.95)
P = 0.0011
Coronary blood flow (CBF) response to acetylcholine in abnormal baseline response (endothelium-dependent CMD), n = 11: −11.0% (−20.15% to 5.85%) to 11.5% (−4.82% to 39.29%)
P = 0.042
Secondary outcomes
CCS angina class
- Improved from 4.0 (3.25-4.0) to 2.0 (2.0-3.0)
- P < 0.001
Seattle Angina Questionnaire (SAQ) scores
- Increase in each SAQ domain
- P < 0.006 for all
Original publication
Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction. JACC Cardiovasc Interv. Published 6 November 2024. doi:10.1016/j.jcin.2024.09.018
Summarised from the published abstract; every number is checked against it